OBJECTIVE: DNA ligase IV syndrome is a rare genetic disorder characterized by pronounced radiosensitivity, growth failure, pancytopenia, hypogonadism, and immunodeficiency. Here, we describe a unique case of DNA ligase IV syndrome diagnosed in adulthood and review the endocrine manifestations of this rare disorder. METHODS: We present detailed clinical, laboratory, and exam findings and review the relevant literature. RESULTS: This patient initially presented in childhood with microcephaly, growth failure, and mild pancytopenia. At age 18, she developed secondary amenorrhea, with labs revealing hypergonadotropic hypogonadism. She was initially suspected to have Turner syndrome, but karyotype testing was normal. At age 34, genetic testing ultimately confirmed the diagnosis of DNA ligase IV syndrome. CONCLUSION: Severe growth failure and hypogonadism are important endocrine clues to the diagnosis of DNA ligase IV syndrome. The increased availability of genetic testing and whole-exome sequencing may allow for definitive diagnosis in patients that previously went unrecognized.
OBJECTIVE: DNA ligase IV syndrome is a rare genetic disorder characterized by pronounced radiosensitivity, growth failure, pancytopenia, hypogonadism, and immunodeficiency. Here, we describe a unique case of DNA ligase IV syndrome diagnosed in adulthood and review the endocrine manifestations of this rare disorder. METHODS: We present detailed clinical, laboratory, and exam findings and review the relevant literature. RESULTS: This patient initially presented in childhood with microcephaly, growth failure, and mild pancytopenia. At age 18, she developed secondary amenorrhea, with labs revealing hypergonadotropic hypogonadism. She was initially suspected to have Turner syndrome, but karyotype testing was normal. At age 34, genetic testing ultimately confirmed the diagnosis of DNA ligase IV syndrome. CONCLUSION: Severe growth failure and hypogonadism are important endocrine clues to the diagnosis of DNA ligase IV syndrome. The increased availability of genetic testing and whole-exome sequencing may allow for definitive diagnosis in patients that previously went unrecognized.
Authors: Tawfeg I Ben-Omran; Karen Cerosaletti; Patrick Concannon; Sheila Weitzman; Marjan M Nezarati Journal: Am J Med Genet A Date: 2005-09-01 Impact factor: 2.802
Authors: E Riballo; S E Critchlow; S H Teo; A J Doherty; A Priestley; B Broughton; B Kysela; H Beamish; N Plowman; C F Arlett; A R Lehmann; S P Jackson; P A Jeggo Journal: Curr Biol Date: 1999-07-01 Impact factor: 10.834
Authors: Jennie E Murray; Louise S Bicknell; Gökhan Yigit; Angela L Duker; Margriet van Kogelenberg; Sara Haghayegh; Dagmar Wieczorek; Hülya Kayserili; Michael H Albert; Carol A Wise; January Brandon; Tjitske Kleefstra; Adilia Warris; Michiel van der Flier; J Steven Bamforth; Kurston Doonanco; Lesley Adès; Alan Ma; Michael Field; Diana Johnson; Fiona Shackley; Helen Firth; C Geoffrey Woods; Peter Nürnberg; Richard A Gatti; Matthew Hurles; Michael B Bober; Bernd Wollnik; Andrew P Jackson Journal: Hum Mutat Date: 2013-11-08 Impact factor: 4.878
Authors: Douglas R Stewart; Alexander Pemov; Jennifer J Johnston; Julie C Sapp; Meredith Yeager; Ji He; Joseph F Boland; Laurie Burdett; Christina Brown; Richard A Gatti; Blanche P Alter; Leslie G Biesecker; Sharon A Savage Journal: PLoS One Date: 2014-06-03 Impact factor: 3.240
Authors: Peter Gullickson; Yunwen W Xu; Laura J Niedernhofer; Elizabeth L Thompson; Matthew J Yousefzadeh Journal: Front Immunol Date: 2022-04-01 Impact factor: 8.786